RVMDW vs RTGN: Which is Better to Buy in 2026?

Side-by-side fundamental comparison based on AI analysis of SEC filings

AI Verdict

RTGN has stronger fundamentals based on our AI analysis.

RVMDW
Revolution Medicines, Inc.
STRONG SELL
88%
Confidence
VS
RTGN
RetinalGenix Technologies Inc.
STRONG SELL
95%
Confidence

RVMDW vs RTGN Fundamental Comparison

Metric RVMDW RTGN
Revenue $0.0 N/A
Net Income $-1.1B $-1.8M
Net Margin N/A N/A
ROE -69.3% N/A
ROA -48.0% -25,788.7%
Current Ratio 7.14x 0.00x
Debt/Equity 0.00x N/A
EPS $-5.95 $-0.10

Green = Better metric | Red = Weaker metric

View Full RVMDW Analysis →
View Full RTGN Analysis →
Browse Sectors: Technology Healthcare Finance Energy Consumer Industrial
Stock Lists: Strong Buy Undervalued Growth Dividend

You Might Also Compare

RVMDW vs AAPL RTGN vs MSFT RVMDW vs GOOGL RTGN vs AMZN

RVMDW vs RTGN: Frequently Asked Questions

Is RVMDW or RTGN a better buy in 2026?

Based on dual AI fundamental analysis (Claude and ChatGPT), RTGN has stronger fundamentals. RVMDW is rated STRONG SELL (88% confidence) while RTGN is rated STRONG SELL (95% confidence). This is not investment advice.

How does RVMDW compare to RTGN fundamentally?

Revolution Medicines, Inc. has ROE of -69.3% vs RetinalGenix Technologies Inc.'s N/A. Net margins are N/A vs N/A respectively.

Which stock pays higher dividends, RVMDW or RTGN?

RVMDW has a dividend yield of N/A or no dividend while RTGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.

Should I invest in RVMDW or RTGN for long term?

For long-term investing, consider that RVMDW has STRONG SELL rating with 88% confidence, while RTGN has STRONG SELL rating with 95% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.

What do the AI models say about RVMDW vs RTGN?

Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RVMDW vs RTGN, the AI consensus favors RTGN based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.